Use of partial AUC to demonstrate bioequivalence of Zolpidem Tartrate Extended Release formulations.
about
Metrics for the evaluation of bioequivalence of modified-release formulationsExperimental models for predicting drug absorption and metabolism.Innovative approaches for demonstration of bioequivalence: the US FDA perspective.Preparation of a liposomal delivery system and its in vitro release of rapamycin.Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation: Report of an FDA Public WorkshopKozeny-Carman permeability relationship with disintegration process predicted from early dissolution profiles of immediate release tablets.
P2860
Use of partial AUC to demonstrate bioequivalence of Zolpidem Tartrate Extended Release formulations.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Use of partial AUC to demonstr ...... Extended Release formulations.
@en
Use of partial AUC to demonstr ...... Extended Release formulations.
@nl
type
label
Use of partial AUC to demonstr ...... Extended Release formulations.
@en
Use of partial AUC to demonstr ...... Extended Release formulations.
@nl
prefLabel
Use of partial AUC to demonstr ...... Extended Release formulations.
@en
Use of partial AUC to demonstr ...... Extended Release formulations.
@nl
P2093
P2860
P1476
Use of partial AUC to demonstr ...... Extended Release formulations.
@en
P2093
Andre S Raw
Lawrence X Yu
Robert A Lionberger
Stephanie H Kim
Xinyuan Zhang
P2860
P304
P356
10.1007/S11095-011-0662-8
P577
2012-01-26T00:00:00Z